Vogt-Koyanagi-Harada syndrome is an autoimmune granulomatous inflammatory disorder targeting melanocytes in the uveal tract, meninges, inner ear and skin.
The disease typically progresses through prodromal, acute uveitic, convalescent and chronic recurrent stages. Delayed or inadequate treatment may result in chronic inflammation and vision-threatening complications such as choroidal neovascular membrane.
The management of Vogt-Koyanagi-Harada (VKH) syndrome becomes significantly more complex in patients with systemic comorbidities such as diabetes. Corticosteroids remain the mainstay of